Immunological Interactions and Inflammatory Changes in the Pathways of Benign Prostatic Hyperplasia and Prostate Cancer
DOI:
https://doi.org/10.54153/sjpas.2025.v7i2.1026Keywords:
Prostate, Benign Prostatic Hyperplasia (BPH), Prostate Cancer (PCa), Cytokines, Interleukins (IL-6, IL-8), Tumor Necrosis Factor Alpha (TNF-α), C-Reactive ProteinAbstract
The prostate is unity of the accessory glands in the male reproductive system and plays a crucial role in maintaining sperm vitality by secreting components that form part of the semen. Prostate diseases, such as benign prostatic hyperplasia (BPH) and prostate cancer (PCa), are associated with inflammatory changes that affect male fertility. Research suggests that prostatitis may be a precursor to the development of these conditions. The study included 84 men aged 35-79 years, divided into three groups: benign prostatic hyperplasia (HP), prostate cancer (PCa), and a control group. Cytokine concentrations of IL-6, IL-8, TNF-α, and C-reactive protein were measured using ELISA. The results showed significant differences between groups in IL-8 levels, with the prostate cancer group recording the highest concentration. No significant differences were observed in IL-6 levels. Significant differences were noted in TNF-α and C-reactive protein levels between groups. Previous research highlights the role of cytokines in the development of prostate cancer, but data on their specific role is limited. Elevated IL-6 and IL-8 levels are associated with increased prostate-specific antigen (PSA) and disease progression. Moreover, elevated TNF-α and C-reactive protein levels are linked to in assistance of benign and malignant prostatic hyperplasia. This study provides additional evidence of the role of cytokines in the development of prostate diseases, underscoring the importance of targeting these molecules in diagnosis and treatment.
References
1. Geller, J. (1989). Pathogenesis and medical treatment of benign prostatic hyperplasia. Prostate Supplement, 2, 95-104.
2. Wagenlehner, F., (2013). Prostatitis and andrological implications. Minerva Urologica e Nefrologica, 65, 117-123.
3. Ficarra, V., (2014). The role of prostatic inflammation in low urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Current Urology Reports, 15, 463-469.
4. Wagenlehner, F. M. E., (2007). The role of inflammation and infection in the pathogenesis of prostate carcinoma. BJU International, 100, 733-737.
5. Roberts, R. O., Lieber, M. M., Bostwick, D. G., & Jacobsen, S. J. (1997). A review of clinical and pathological prostatitis syndromes. Urology, 49, 809-821.
6. Roehrborn, C. G., & McConnell, J. D. (2007). Benign prostatic hyperplasia: Etiology, pathophysiology, epidemiology, and natural history. In A. J. Wein, L. R. Kavoussi, A. W. Partin, & C. A. Peters (Eds.), Campbell-Walsh Urology (9th ed., p. 2727). Saunders.
7. Gravas, S., Cornu, J. N., Drake, M. J., Gacci, M., Gratzke, C., Herrmann, T. R. W., et al. (2018). Management of non-neurogenic male lower urinary tract symptoms (LUTS). Limited update March 2018.
8. Attard, G., Parker, C., Eeles, R. A., Schrader, A. J., Fizazi, K., & Tombal, B. (2016). Prostate cancer. The Lancet, 387(10013), 70-82.
9. Zlotta, A. R., (2013). Prevalence of prostate cancer on autopsy: Cross-sectional study on unscreened Caucasian and Asian men. Journal of the National Cancer Institute, 105, 1050-1058.
10. McNaughton Collins, M., Pontari, M. A., O'Leary, M. P., Calhoun, E. A., Santanna, J., Landis, J. R., (2001). Quality of life is impaired in men with chronic prostatitis: The Chronic Prostatitis Collaborative Research Network. Journal of General Internal Medicine, 16(10), 656-662.
11. Nickel, J. C., Olson, M. E., Barbas, A., Benediktsson, H., Dasgupta, M. K., & Costerton, J. W. (1990). Pathogenesis of bacterial prostatitis in an animal model. British Journal of Urology, 66(1), 47-54.
12. Pontari, M. A., Joyce, G. F., Wise, M., & McNaughton-Collins, M. (2007). Urologic Diseases in America project: Prostatitis. The Journal of Urology, 177(6), 2050.
13. Dinarello, C. A. (2007). Historical review of cytokines. European Journal of Immunology, 37(Suppl. 1), S34-S45.
14. Turner, M. D., Nedjai, B., Hurst, T., & Pennington, D. J. (2014). Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochimica et Biophysica Acta (BBA) – Molecular Cell Research, 1843, 2563-2582.
15. O’Shea, J. J., Ma, A., & Lipsky, P. (2002). Cytokines and autoimmunity. Nature Reviews Immunology, 2, 37-45.
16. Bradley, J. (2008). TNF-mediated inflammatory disease. Journal of Pathology, 214, 149-160. Available at: [Google Scholar] [CrossRef].
17. Helson, L., Helson, C., & Green, S. (1979). Effect of murine tumor necrosis factor on heterotransplanted human tumors. Experimental Cell Biology, 47(1), 53-60.
18. Muenchen, H., & Aggarwal, S. (1998). Enhanced immune system activation after treatment with novel antineoplastic platinum agents. Anticancer Research, 18(5), 2631-2636.
19. Claudio, E., Segade, F., Wrobel, K., Ramos, S., & Bravo, R. (1996). Molecular mechanisms of TNF-α cytotoxicity: Activation of NF-κB and nuclear translocation. Experimental Cell Research, 224(1), 63-71.
20. Luettig, B., Decker, T., & Lohmann-Matthes, M. L. (1989). Evidence for the existence of two forms of membrane tumor necrosis factor: An integral protein and a molecule attached to its receptor. Journal of Immunology, 143(12), 4034-4038.
21. Hu, S., Liang, S., Guo, H., Zhang, D., Li, H., Wang, X., Yang, W., Qian, W., Hou, S., & Wang, H. (2013). Comparison of the inhibition mechanisms of Adalimumab and Infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. Journal of Biological Chemistry, 288, 27059–27067.
22. Akdis, M., Burgler, S., Crameri, R., Eiwegger, T., Fujita, H., Gomez, E., et al. (2011). Interleukins, from 1 to 37, and interferon-gamma: Receptors, functions, and roles in diseases. Journal of Allergy and Clinical Immunology, 127, 701-721.e1-70.
23. Rose-John, S. (2018). Interleukin-6 family cytokines. Cold Spring Harbor Perspectives in Biology, 10, a028415. https://doi.org/10.1101/cshperspect.a028415
24. Delves, P. J., Martin, S. J., Burton, D. R., & Roitt, I. M. (2011). Roitt’s Essential Immunology (12th ed.). Oxford: Blackwell Publishing Limited.
25. Graves, D. T., & Chemokines, J. Y. (1995). A family of chemotactic cytokines. Critical Reviews in Oral Biology and Medicine: An Official Publication of the American Association of Oral Biologists, 6, 109-111.
26. Lan, T., Chen, L., & Wei, X. (2021). Inflammatory cytokines in cancer: Comprehensive understanding and clinical progress in gene therapy. Cells, 10(1), 100. https://doi.org/10.3390/cells10010100
27. Archer, M., Dogra, N., & Kyprianou, N. (2020). Inflammation as a driver of prostate cancer metastasis and therapeutic resistance. Cancers (Basel), 12(10), 2984.
28. British Society for Immunology. (2024). Contact information. [online] Available at: https://www.immunology.org/contact-us [Accessed 17 August 2024].
29. MyBioSource. (2024). Human Interleukin 6 (IL6) ELISA Kit. Product Code: [Product Code]. Available at: [URL]. For research use only. Not for use in diagnostic procedures.
30. MyBioSource. (2024). Human Interleukin 8 (IL8) ELISA Kit. Product Synonym Names: CXCL8, AMCF-I, GCP1, K60, LECT, LUCT, LYNAP, MDNCF, MONAP, NAF, NAP1, SCYB8, TSG1, B-ENAP, Neutrophil-Activating Protein 1, Granulocyte Chemotactic Protein 1. Product Gene Name: IL8 ELISA Kit. Available at: [URL]. For research use only. Not for use in diagnostic procedures.
31. MyBioSource. (2024). Human TNF alpha ELISA Kit. Product Code: [Product Code]. Available at: [URL]. For research use only. Not for use in diagnostic procedures.
32. Demeditec Diagnostics. (2024). CRP Canine ELISA (DE1024). Available at: https://www.demeditec.com [Accessed 17 August 2024].
33. Duncan, D. B. (1955). Multiple range and multiple F tests. Biometrics, 11(1), 1-42.
34. Katongole, P., Sande, O. J., Nabweyambo, S., Joloba, M., Kajumbula, H., & Kalungi, S. (2021). IL-6 and IL-8 cytokines are associated with elevated prostate-specific antigen levels among patients with adenocarcinoma of the prostate at the Uganda Cancer Institute. Journal of Cancer Research and Therapeutics, 17(3), 661–667. https://doi.org/10.1080/xxxxxx.2021.202xxx
35. Maynard, J. P., Ertunc, O., Kulac, I., Baena-Del Valle, J. A., De Marzo, A. M., & Sfanos, K. S. (2020). IL8 expression is associated with prostate cancer aggressiveness and androgen receptor loss in primary and metastatic prostate cancer. Molecular Cancer Research, 18, 153–165.
36. Culig, Z., & Puhr, M. (2018). Interleukin-6 and prostate cancer: Current developments and unsolved questions. Molecular and Cellular Endocrinology, 462, 25-30.
37. Al-Fartosy, A. J. M., & Ati, M. H. (2021). The relationship of insulin resistance with some proinflammatory markers in prostate cancer and benign prostate hyperplasia patients. Annals of R.S.C.B., 25(6), 14186-14194. http://annalsofrscb.ro [Accessed 20 August 2024].
38. O’Brian, D., Prunty, M., Hill, A., & Shoag, J. (2021). The role of C-reactive protein in kidney, bladder, and prostate cancers. Frontiers in Immunology, 12, 721989. https://doi.org/10.3389/fimmu.2021.721989
39. Sameen, A. M., Shabeeb, I. A., & Rashied, R. M. (2023). The role of inflammatory processes and zinc levels in prostatic enlargement among Iraqi samples. Journal of Medical Laboratory. [Volume], [Page Range]. https://doi.org/10.25122/jml-2023-0224
40. Elahi, M. M., Asotra, K., Matata, B. M., & Mastana, S. S. (2009). Tumor necrosis factor alpha −308 gene locus promoter polymorphism: An analysis of association with health and disease. BBA Molecular Basis of Disease, 1792, 163-172.
41. Chikazawa, M., Yoshitake, J., Lim, S. Y., Negishi, L., Shibata, T., & Uchida, K. (2020). Glycolaldehyde is an endogenous source of lysine N-pyrrolation. Journal of Biological Chemistry, 295(48), 16393-16403. https://doi.org/10.1074/jbc.RA120.013179.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright Notice
Authors retain copyright and grant the SJPAS journal right of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in Samarra Journal of Pure and Applied Science.
The Samarra Journal of Pure and Applied Science permits and encourages authors to archive Pre-print and Post-print items submitted to the journal on personal websites or institutional repositories per the author's choice while providing bibliographic details that credit their submission, and publication in this journal. This includes the archiving of a submitted version, an accepted version, or a published version without any Risks.
